Page last updated: 2024-10-24

astrocyte cell migration

Definition

Target type: biologicalprocess

The orderly movement of an astrocyte, a class of large neuroglial (macroglial) cells in the central nervous system, the largest and most numerous neuroglial cells in the brain and spinal cord. [CL:0000127, GOC:go_curators]

Astrocyte cell migration is a complex process involving a coordinated interplay of signaling pathways, cytoskeletal rearrangements, and interactions with the extracellular matrix. It is essential for proper brain development, wound healing, and responses to injury.

Here's a detailed breakdown of the process:

1. **Stimulus Recognition:** Astrocytes possess receptors that detect signals from their environment, including:
* **Neurotransmitters:** Astrocytes respond to neurotransmitters like glutamate and ATP, released by neurons.
* **Cytokines:** Inflammatory signals like TNF-α and IL-1β can trigger migration.
* **Extracellular Matrix Components:** Astrocytes interact with proteins like laminin and fibronectin in the extracellular matrix, which can influence their movement.

2. **Signal Transduction:** Receptor activation initiates intracellular signaling cascades that lead to changes in gene expression and protein activity:
* **Calcium Signaling:** Stimulation often causes a rise in intracellular calcium levels, which activates downstream signaling pathways.
* **MAP Kinase Pathway:** This pathway is involved in cell proliferation, survival, and migration.
* **PI3K/Akt Pathway:** This pathway is essential for cell survival and motility.

3. **Cytoskeletal Rearrangements:** Changes in the cytoskeleton, particularly actin and microtubules, are crucial for migration:
* **Actin Polymerization:** Actin filaments assemble at the leading edge of the migrating cell, forming protrusions called lamellipodia and filopodia.
* **Microtubule Dynamics:** Microtubules provide tracks for organelle transport and contribute to cell polarity.

4. **Adhesion and Detachment:** Astrocytes adhere to the extracellular matrix, and this adhesion needs to be regulated during migration:
* **Integrins:** These transmembrane proteins mediate cell adhesion and signaling.
* **Focal Adhesions:** These specialized structures form at the leading edge of the cell and anchor actin filaments to the extracellular matrix.

5. **Cell Polarization:** During migration, astrocytes develop a distinct polarity:
* **Leading Edge:** The front of the cell, where lamellipodia and filopodia extend.
* **Trailing Edge:** The rear of the cell, where the cell detaches from the substrate.

6. **Migration Mechanisms:** Astrocytes can migrate using different mechanisms, including:
* **Amoeboid Migration:** A relatively fast and less directional mode of migration involving the formation of pseudopodia.
* **Mesenchymal Migration:** A more directional mode of migration requiring cell adhesion and traction forces.

7. **Regulation of Migration:** Astrocyte migration is tightly regulated by various factors:
* **Growth Factors:** Factors like EGF and PDGF can stimulate astrocyte migration.
* **Chemotaxis:** Astrocytes can migrate toward specific chemical attractants, like neurotransmitters or chemokines.
* **Contact Guidance:** Astrocytes can migrate along specific pathways within the brain, guided by cues from the extracellular matrix.

8. **Functions of Astrocyte Migration:** Astrocyte migration plays critical roles in various physiological and pathological processes:
* **Brain Development:** Astrocytes migrate during embryogenesis to establish their proper positions in the brain.
* **Wound Healing:** Astrocytes migrate to sites of injury to promote repair and limit damage.
* **Neuroinflammation:** Astrocyte migration contributes to the inflammatory response in the brain.
* **Tumor Invasion:** Astrocytes can be involved in the spread of brain tumors.

9. **Clinical Implications:** Disruptions in astrocyte migration can contribute to various neurological disorders:
* **Neurodevelopmental Disorders:** Defects in astrocyte migration during development can lead to neurological disorders.
* **Neurodegenerative Diseases:** Astrocytes can migrate to areas of neuronal damage, contributing to disease progression.
* **Brain Tumors:** Aberrant astrocyte migration can contribute to the spread of brain tumors.

Astrocyte migration is a complex and multifaceted process with far-reaching implications for brain development, health, and disease. Understanding the mechanisms underlying astrocyte migration is crucial for developing new therapies for neurological disorders.'
"

Proteins (4)

ProteinDefinitionTaxonomy
Nuclear receptor subfamily 2 group E member 1A nuclear receptor subfamily 2 group E member 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y466]Homo sapiens (human)
Matrix metalloproteinase-14A matrix metalloproteinase-14 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P50281]Homo sapiens (human)
C-C motif chemokine 2A C-C motif chemokine 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P13500]Homo sapiens (human)
Beta-hexosaminidase subunit betaA beta-hexosaminidase subunit beta that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07686]Homo sapiens (human)

Compounds (40)

CompoundDefinitionClassesRoles
fasudilfasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

fasudil: intracellular calcium antagonist; structure in first source
isoquinolines;
N-sulfonyldiazepane
antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
propafenonepropafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.

Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
aromatic ketone;
secondary alcohol;
secondary amino compound
anti-arrhythmia drug
propranololpropranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
naphthalenes;
propanolamine;
secondary amine
anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
pyrimethamineMaloprim: contains above 2 cpdsaminopyrimidine;
monochlorobenzenes
antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
dexpropranololpropranolol
tiludronic acidtiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first sourceorganochlorine compound
epigallocatechin gallate(-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.

epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis)
flavans;
gallate ester;
polyphenol
antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
zoledronic acidzoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.

Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.
1,1-bis(phosphonic acid);
imidazoles
bone density conservation agent
tryptolinetryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structurebeta-carbolines
tadalafilbenzodioxoles;
pyrazinopyridoindole
EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
marimastatmarimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.

marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary
hydroxamic acid;
secondary carboxamide
antineoplastic agent;
matrix metalloproteinase inhibitor
2-acetamido-1,5-imino-1,2,5-trideoxy-d-glucitol2-acetamido-1,5-imino-1,2,5-trideoxy-D-glucitol: structure given in first source
ilomastatCS 610: matrix metalloproteinase inhibitor; structure in first source

ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor
hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid
anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
n-desisopropylpropranololN-desisopropylpropranolol: RN given refers to parent cpd
cgs 27023aCGS 27023A: a matrix metalloproteinase inhibitor
y 27632Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source

Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.
aromatic amide
prinomastatprinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14.

prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor;
aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor
ha 1100HA 1100: intracellular calcium antagonist
rs-130830RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor
tmi-1
n-acetylglucosamine thiazolineN-acetylglucosamine thiazoline: an analog of the oxazolinium bicyclic intermediate leading from N-acetylglucosamine to 1,6-anhydro-N-acetylmuramic acid
batimastatbatimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor.

batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor
hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide
angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor
ik 682IK 682: inhibits TNF-alpha converting enzyme; structure in first sourcehydroxamic acid;
pyrrolidin-2-ones;
quinolines
epigallocatechin-3-o-(3''-o-methyl)-gallatecatechin
ro 32-3555Ro 32-3555: structure given in first source
sb 3ct compoundSB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first sourcearomatic ether
pd 166793
sc 78080
ro 31-9790Ro 31-9790: hydroxamic acid derivative
incb3344INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist
arp-100
kb r8301
N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamideN(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide : A hydroxamic acid that is N-hydroxy-D-valinamide in which the alpha-amino group has been substituted by isopropoxy and [biphenyl]-4-ylsulfonyl groups. A selective matrix metalloproteinase-2 (MMP-2) inhibitor, it is one of the most potent inducers of autophagy. Its physiological roles include angiogenesis, cancer metastasis, embryogenesis, tissue remodeling in development, and wound healing.D-valine derivative;
hydroxamic acid
antineoplastic agent;
autophagy inducer;
EC 3.4.24.24 (gelatinase A) inhibitor;
melanin synthesis inhibitor
bms-566394BMS-566394: structure in first source
incb3619INCB3619: ADAM inhibitor; structure in first source
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile6-aminopurines
6-(3,5-difluoroanilino)-9-(2,2-difluoroethyl)-2-purinecarbonitrile6-aminopurines
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrileimidazoles
grassystatin agrassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source
thiamet g